Sarepta Therapeutics, Inc. (SRPT)
15.98
-0.03
(-0.19%)
USD |
NASDAQ |
Nov 13, 09:56
Sarepta Therapeutics Free Cash Flow (Quarterly) : 53.83M for Sept. 30, 2026
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 53.83M |
| June 30, 2026 | 196.52M |
| March 31, 2026 | -205.76M |
| December 31, 2025 | 123.20M |
| September 30, 2025 | -54.96M |
| June 30, 2025 | 229.35M |
| March 31, 2025 | -629.33M |
| December 31, 2024 | 53.96M |
| September 30, 2024 | -107.96M |
| June 30, 2024 | -14.22M |
| March 31, 2024 | -284.52M |
| December 31, 2023 | -73.70M |
| September 30, 2023 | -155.62M |
| June 30, 2023 | -140.14M |
| March 31, 2023 | -218.88M |
| December 31, 2022 | -100.36M |
| September 30, 2022 | -73.20M |
| June 30, 2022 | -75.89M |
| March 31, 2022 | -106.73M |
| December 31, 2021 | -31.53M |
| September 30, 2021 | -133.57M |
| June 30, 2021 | -115.04M |
| March 31, 2021 | -201.52M |
| December 31, 2020 | -206.64M |
| September 30, 2020 | -263.49M |
| Date | Value |
|---|---|
| June 30, 2020 | -126.77M |
| March 31, 2020 | 618.67M |
| December 31, 2019 | -186.42M |
| September 30, 2019 | -77.45M |
| June 30, 2019 | -96.28M |
| March 31, 2019 | -163.35M |
| December 31, 2018 | -143.18M |
| September 30, 2018 | -134.49M |
| June 30, 2018 | -126.83M |
| March 31, 2018 | -48.51M |
| December 31, 2017 | -35.58M |
| September 30, 2017 | -65.66M |
| June 30, 2017 | -88.37M |
| March 31, 2017 | -63.60M |
| December 31, 2016 | -84.58M |
| September 30, 2016 | -61.78M |
| June 30, 2016 | -44.06M |
| March 31, 2016 | -62.27M |
| December 31, 2015 | -32.81M |
| September 30, 2015 | -47.80M |
| June 30, 2015 | -29.42M |
| March 31, 2015 | -44.27M |
| December 31, 2014 | -28.91M |
| September 30, 2014 | -48.22M |
| June 30, 2014 | -44.35M |
Free Cash Flow Definition
Free Cash Flow is the cash a company has left after paying for its day-to-day operations and investing in its physical assets, such as buildings, equipment and technology. The company can use that cash however it chooses: paying dividends, buying back shares, paying down debt, making acquisitions or keeping it for future growth.
Free Cash Flow (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow (Quarterly) Benchmarks
| Beam Therapeutics, Inc. | -111.96M |
| Moderna, Inc. | -1.68B |
| Rocket Pharmaceuticals, Inc. | -39.62M |
| Intellia Therapeutics, Inc. | -86.32M |
| Arrowhead Pharmaceuticals, Inc. | -181.32M |